



#### **Fund Characteristics**

AUM	€ 1016.87 Mln
Fund Launch date	28/09/1990
Share Class Launch Date	28/09/1990

ISIN	LU0093570330
Reference currency	EUR
Legal structure	UCIT
Domicile	LU
European Passport	Yes
Countries of registration	

AT, BE, CH, DE, DK, ES, FI, FR, GB, IT, LU, NL,

NO, PT, SE, SG
Risk Indicator (SRI)
SFDR Classification

#### Reference Index

MSCI Europe NR EUR

Fund Manager	Deputy
Ivan Bouillot	Tom Michels





#### **Management Company**

www.bli.lu

BLI - Banque de Luxembourg Investments 16, Boulevard Royal L-2449 Luxembourg Tel: (+352) 26 26 99 - 1

**Dealing & Administrator Details** 

UI efa S.A.	
Telephone	+352 48 48 80 582
Fax	+352 48 65 61 8002
Dealing frequency	daily1
Cut-off-time	12:00 CET
Front-load fee	max. 5%
Redemption fee	none
NAV calculation	daily¹
NAV publication	www.fundinfo.com

<sup>&</sup>lt;sup>1</sup> Luxembourg banking business day

#### **Investment Objective**

The fund's objective is to generate long-term capital gains by investing in high-quality European companies which have a sustainable competitive advantage and a sound ESG (environmental, social and governance) profile. It aims to achieve higher risk-adjusted returns than its benchmark universe over a full market cycle. A minimum of 30% of the fund's assets will be invested in sustainable assets.

The fund manager implements an active, long-term strategy based on solid convictions.

### **Key Facts**

- An active, fundamental, conviction-based approach (30 to 40 stocks), purely bottom-up and oriented towards the long term;
- As well as valuation, constant attention is paid to the financial and extra-financial quality of the companies in the portfolio;
- Integration of ESG factors at different stages of the investment process (exclusions, analysis, valuation, monitoring of controversies, voting policy and engagement);
- Regular review of the valuation of each stock and the average valuation of the portfolio;
- Non-benchmarked management resulting in significant deviations from the initial investment universe;
- · Low turnover.

#### **Fund Performance**

Past performance does not predict future returns. References to a market index or peergroup are made for comparison purposes only; the market index or peergroup are not mentioned in the investment policy of the sub-fund. Investors are also invited to consult the performance chart disclosed in the key information document of the shareclass.



Yearly Performance	YTD	2024	2023	2022	2021	2020
B EUR Acc	-1.3%	1.5%	11.6%	-23.6%	25.5%	-0.6%
Reference Index	5.0%	8.6%	15.8%	-9.5%	25.1%	-3.3%

Cumulative Performance	1 Month	1 year	3 years	5 years	10 years
B EUR Acc	-0.5%	-1.7%	-2.2%	17.8%	38.4%
Reference Index	-0.8%	6.9%	27.1%	76.1%	71.2%
Annualized Performance		1 year	3 years	5 years	10 years
Annualized Performance B EUR Acc		1 year -1.7%	3 years -0.7%	5 years 3.3%	10 years 3.3%

Annualized Volatility	1 year	3 years	5 years	10 years
B EUR Acc	16.3%	13.7%	13.5%	14.6%
Reference Index	18.2%	14.7%	14.1%	16.8%





## **Top 10 Holdings**

Nestle	4.6%
AstraZeneca PLC	3.9%
ASML HOLDING NV	3.9%
Wolters Kluwer	3.7%
Schneider Electric	3.6%
SGS	3.6%
Air Liquide	3.5%
Unilever	3.4%
SAP	3.4%
LVMH	3.4%

#### **Summary Statistics**

Weight of Top 10	37.1%
Number of holdings	45
Active Share vs MSCI Europe	74.2%
% Sustainable Assets	68%

#### **New investments**


Kone

#### Investments sold


Ashtead Group Plc Compass Group Plc Ferguson Enterprises Novartis

### **Currency Allocation**


EUR	55.0%
CHF	21.1%
GBP	11.8%
DKK	7.2%
SEK	4.8%
Other	0.0%



## **Country Allocation**



### Market Cap Allocation in EUR







European markets ended April on a downward note. Global equity markets fell sharply after Donald Trump announced the introduction of significantly higher-than-expected tariffs on 2 April. The tariffs he announced raised concerns about global growth (the IMF cut forecasts from 3.3% to 2.8% for 2025) and fuelled the risk of escalation by key partners. Faced with this trade war and the ensuing risks, particularly for the public deficit, investors steered away from US assets, causing the dollar to fall and US sovereign yields to rise (to 4.50% for the US 10-year Treasury note). Trump then declared a 90-day truce for all countries except China, giving the markets some breathing space, before surprising everyone again with an announcement that tariffs on Chinese imports would be raised to 145%. China immediately raised its own tariffs on US products to 125%, exacerbating tensions and reigniting fears of a prolonged trade war. Trump then temporarily exempted Chinese imports of technology products and electronic components (with tariffs reduced to 20%). The immediate question is whether negotiations are possible now that Trump has opened the door to talks. The Fed chairman deemed it unnecessary to adjust key interest rates in the short term, given the inflationary risk posed by the US tariff hike. In the eurozone, April's PMI indices sent a negative signal with a decline in new orders that suggests a slowdown in activity. However, industrial production remains solid in the short term, although this is partly due to anticipation of the introduction of customs barriers.

During the month, the sectors posting the biggest gains were real estate, utilities, consumer durables and telecommunications. Other sectors declined, especially energy. The European large cap index (MSCI Europe Net Return EUR) fell by 0.8%, while the European small and mid cap index (MSCI Europe SMID Cap Net Return EUR) gained 2.4%.

Standing out among the biggest individual contributions were L'Oréal, Wolters Kluwer, Nestlé, Novonesis and Kone. Irrespective of company results, defensive stocks prevailed in a turbulent market. The main negative contributors were LVMH, AstraZeneca, Novo Nordisk, Roche and Novartis. LVMH suffered from a lacklustre trading update, with a 3% decline in sales attributable to weaker-than-expected demand in China. Pharmaceutical stocks fell due to uncertainty over potential, as yet unannounced, measures that the Trump administration may implement in the sector.

At the beginning of the month, the portfolio's exposure to the healthcare sector was scaled back, with the reduction of positions in Roche and AstraZeneca and the sale of Novartis. The positions in EssilorLuxottica, Deutsche Boerse and Air Liquide were trimmed due to their valuations. Compass, Ashtead and Ferguson were sold to reduce exposure to the economic situation in the United States. At the same time, the positions in Assa Abloy, SGS, UMG and Coloplast were increased. A new position was also added to the portfolio: Kone. Kone is a global leader in vertical transport solutions (lifts, escalators) with a strong presence in Asia, especially China. Its business model, focusing on recurring services (maintenance and modernisation), ensures stable and predictable profitability. Sustainable demand is underpinned by increasing urbanisation, city densification and the transition to smart buildings. Kone is investing in digital innovation, strengthening its competitiveness. Its financial strength, healthy balance sheet and robust margins make it a high-quality defensive stock that is well positioned to benefit from global urban megatrends.





Investor Type	Clean Share	Share class	Curr.	Income	Mgmt Fees	On-going charges	ISIN	Bloomberg Ticker
Institutional	No	BI	EUR	Acc	0.60%	0.71%	LU0439765321	BLEQEIC LX
Retail	No	Α	EUR	Dis	1.25%	1.42%	LU0439765081	BLEQEUA LX
Retail	Yes	AM	EUR	Dis	0.85%	1.08%	LU1484141491	BLEQAMD LX
Retail	No	В	EUR	Acc	1.25%	1.41%	LU0093570330	BLE4725 LX
Retail	No	B CHF Hedged	CHF	Acc	1.25%	1.41%	LU1305477884	BLEQBCH LX
Retail	No	B USD Hedged	USD	Acc	1.25%	1.41%	LU1273297371	BLEEBUH LX
Retail	Yes	BM	EUR	Acc	0.85%	1.03%	LU1484141574	BLEQEBM LX
Retail	Yes	BM CHF Hedged	CHF	Acc	0.85%	1.01%	LU1484141657	BLEQBMC LX
Retail	Yes	BM USD Hedged	USD	Acc	0.85%	1.00%	LU1484141731	BLEQBMU LX

against market fluctuations, you could lose

your entire investment.

	Opportunities		Risks
	Benefit from an exposure to quality European companies with no a priori constraints (sector, market capitalisation, country);	-	Currency risk. The Fund's currency may differ from your reference currency, in which case the final return will depend on the exchange rate between the two currencies.
•	Active, bottom-up, conviction-driven investment approach geared towards the long term:		This risk is not taken into account in the indicators shown above; The sub-fund may also be exposed to other
,	Focus on high-quality growth companies and valuation.		significant risks, which are not included in the synthetic risk indicator: none. Other risk factors may exist; As this product provides no protection



The risk indicator assumes you keep the product for 10 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.





This document has been drawn up by BLI - Banque de Luxembourg Investments ("BLI") and is intended solely for professional investors. It refers directly or indirectly to one or more financial products (the "Financial Product") and constitutes a marketing communication within the meaning of Regulation (EU) 2019/1156 of 20 June 2019 on facilitating cross-border distribution of collective investment undertakings.

The economic, financial and non-financial information contained in this document (the "Information") is provided on the basis of the information known at the date of publication and is subject to change without notice. The Information originates (in whole or in part) from sources external to BLI or is based on such sources. BLI believes it has taken reasonable measures to ensure that the Information is accurate and up-to-date as of the date of this document. However, BLI cannot guarantee the accuracy and/or timeliness of the Information.

The Information does not constitute investment advice, an invitation to invest in the Financial Product, or legal or tax advice.

All recipients of this document should be aware that:

- All investments in the Financial Product entail specific risks, which are detailed in the issue document and in the Key Information Document of the Financial Product.
- The past performance of the Financial Product is no guarantee of its future performance. The value of the Financial Product and the income derived from it may rise or fall and investors may not recover their initial investment.
- Any performance data presented in this document does not take into account any commissions, fees or taxes incurred in connection with the subscription or redemption of units in the Financial Product.
- The Financial Product is not managed by reference to a benchmark index.

In general, BLI assumes no responsibility for the future performance of any Financial Product. BLI cannot be held liable for any decisions that a recipient of this document may or may not make on the basis of the Information. Individuals interested in investing in a Financial Product must ensure the suitability of such an investment for their personal situation and seek independent advice, if needed or in case of doubt. They must also consider the characteristics and objectives of the Financial Product, in particular where reference is made to sustainability-related aspects in accordance with Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability-related disclosures in the financial services sector. This Information is available on BLI's website at <a href="https://www.bli.lu">www.bli.lu</a>.

Investment in the Financial Product may only be made on the basis of the issue document, the Key Information Document and the most recent annual report or semi-annual report of the Financial Product; these documents are in each case in the version in force at the time the investment decision is made (the "Documents"). The Documents are available free of charge upon request by post addressed to BLI – Banque de Luxembourg Investments, 16, boulevard Royal, L-2449 Luxembourg or by e-mail addressed to info@bli.lu. BLI can also indicate the languages in which each Document is available.

Individuals interested in investing in the Financial Product are informed that a summary of their investor rights is available on BLI's website at:

https://www.banquedeluxembourginvestments.com/en/bank/bli/legal-information

Finally, BLI wishes to emphasise that it may decide at any time to cease marketing the Financial Product, subject to compliance with the applicable legal and regulatory provisions.

This document may not be reproduced, in whole or in part, without the prior written consent of BLI.

BLI - Banque de Luxembourg Investments, a management company approved by the *Commission de Surveillance du Secteur Financier Luxembourg (CSSF)* 16, boulevard Royal L-2449 Luxembourg RCS number: B80479.

#### Specific Information concerning MSCI Data:

All MSCI data is provided "as is". Neither MSCI nor any other party involved in or related to compiling, computing or creating the MSCI data makes any express or implied warranties or representations with respect to such data (or the result to be obtained by the use thereof) and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any such data. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in or related to compiling, computing or creating the data have any liability for any direct, indirect, special punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages. No further distribution or dissemination of the MSCI data is permitted without MSCI's express written consent.

### Specific Information concerning GICS Data:

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard and Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed to use by Banque de Luxembourg S.A.. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classification have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if noticed of the possibility of such damages.

#### Specific Information for Switzerland:

Legal documentation of the fund may be obtained, free of charge, at the offices of the Swiss representative, CACEIS (Switzerland) S.A.,7-9, Chemin de Précossy, CH-1260 Nyon, Switzerland, in accordance with the provisions of the Swiss Collective Investment Schemes Act of 23 June 2006 ("CISA"). The SICAV has appointed Banque CIC (Suisse) SA, Marktplatz 13, CH-4001 Bâle, Switzerland to act as paying agent for Switzerland. The present document may be distributed to Swiss qualified investors.

#### Specific Information for France:

The present document may be distributed to French professional investors.